What is Noetik?
Noetik is an AI-native biotechnology enterprise dedicated to transforming cancer therapeutics through the application of self-supervised machine learning. By analyzing high-throughput spatial data, the company identifies novel biological insights that traditional discovery methods often overlook. This data-centric approach allows Noetik to map the tumor microenvironment with unprecedented precision, facilitating the development of more effective, targeted cancer treatments. As an emerging leader in the intersection of artificial intelligence and life sciences, Noetik is redefining the drug discovery paradigm by prioritizing computational rigor and scalable biological modeling.
How much funding has Noetik raised?
Noetik has raised a total of $54M across 2 funding rounds:
Angel/Seed
$14M
Series A
$40M
Angel/Seed (2023): $14M with participation from EPIC Ventures, North South Ventures, Zetta Venture Partners, Catalio Capital Management, Intermountain Ventures, 11.2 Capital, and DCVC Management
Series A (2024): $40M led by Polaris Partners, Wittington Ventures, and Khosla Ventures
Key Investors in Noetik
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise and resources for growth.
Wittington Ventures
Wittington Investments Limited is a private family Canadian company with a diverse portfolio of investments across various sectors, including property and retail.
Khosla Ventures
Khosla Ventures is a prominent venture capital firm focused on early-stage and growth-stage companies, with a strong emphasis on disruptive technology and scientific innovation.
What's next for Noetik?
With the successful closure of its Series A round, Noetik is poised to scale its computational infrastructure and advance its lead therapeutic candidates toward clinical validation. The strategic focus will likely shift toward expanding its internal research capabilities and forging partnerships that leverage its spatial data platform for broader oncology applications. As the company matures, the integration of its AI-native methodology into the drug development lifecycle will be critical in maintaining its competitive edge. Investors are closely monitoring how Noetik will utilize this capital to bridge the gap between high-dimensional data analysis and tangible clinical outcomes in the oncology sector.
See full Noetik company page
